These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 30740950

  • 1. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
    Termrungruanglert W, Khemapech N, Tantitamit T, Havanond P.
    J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
    Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK.
    Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
    van Rosmalen J, de Kok IM, van Ballegooijen M.
    BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
    [Abstract] [Full Text] [Related]

  • 10. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.
    BMJ Open; 2018 Jan 26; 8(1):e016700. PubMed ID: 29374658
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.
    PLoS Med; 2017 Sep 26; 14(9):e1002388. PubMed ID: 28926579
    [Abstract] [Full Text] [Related]

  • 14. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X, Wu Q, Wang X, Fu Y, Zhang X, Tian X, Cheng B, Lu B, Yu X, Lan S, Lu W, Ma D, Cheng X, Xie X.
    Clin Microbiol Infect; 2018 Dec 26; 24(12):1322-1327. PubMed ID: 29518562
    [Abstract] [Full Text] [Related]

  • 15. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.
    Health Technol Assess; 2014 Apr 26; 18(23):1-196. PubMed ID: 24762804
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.